Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-07-24

Clinical Trial Update: Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating switching from oral antipsychotics to long-acting risperidone in people with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Risperidone long-acting injectable (Risperdal Consta) (Risperidone)

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED | Results posted: 2013-07-24